This bill extends the federal government's authority to issue priority review vouchers for drugs and treatments targeting rare pediatric diseases. The vouchers allow pharmaceutical companies developing these treatments to receive expedited FDA review of their applications, which typically speeds up the approval process. The legislation amends existing law to extend this program from its current expiration date of September 30, 2024, through September 30, 2030, giving manufacturers a longer window to develop and seek approval for pediatric treatments. The bill affects pharmaceutical companies working on rare childhood diseases and ultimately benefits children and families suffering from these conditions by incentivizing drug development in areas that might otherwise be unprofitable. No new funding is specified in the legislation, as it operates through the existing voucher program structure.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.